Clinics in Dermatology
Volume 27, Issue 6, Supplement , Pages S44-S47 , November 2009

An open-label, single-center pilot study to determine the antifungal activity of a new nonsteroidal cream (Promiseb Topical Cream) after 7 days of use in healthy volunteers

  • Leon Kircik, MD, FAAD

      Affiliations

    • Corresponding Author InformationDerm Research, PLLC, Louisville, KY 40217-1417, USA. Tel.: +1 502 451 9000.

References 

  1. Bikowski J. Facial seborrheic dermatitis: a report on current status and therapeutic horizons. J Drugs Dermatol. 2009;8:125–133
  2. Naldi L, Rebora A. Seborrheic dermatitis. N Engl J Med. 2009;360:387–396
  3. Faergemann J, Borgers M, Degreef H. A new ketoconazole topical gel formulation in seborrheic dermatitis: an updated review of the mechanism. Expert Opin Pharmacother. 2007;8:1365–1371
  4. Gupta AK, Nicol K, Batra R. Role of antifungal agents in the treatment of seborrheic dermatitis. Am J Clin Dermatol. 2004;5:417–422
  5. Elewski B. An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face. Clin Dermatol. 2009;27(Suppl 2):S48–S53
  6. Veraldi S, Menter A, Innocenti M. Treatment of mild to moderate seborrhoeic dermatitis with MAS064D (Sebclair), a novel topical medical device: results of a pilot, randomized, double-blind, controlled trial. J Eur Acad Dermatol Venereol. 2008;22:290–296
  7. Pechère M, Remondat C, Bertrand C, Didierjean L, Saurat JH. A simple quantitative culture of Malassezia spp. in HIV positive persons. Dermatology. 1995;191:348–349

☆ Dr Kircik is a consultant, an investigator, and serves as a speaker for Promius Pharma, LLC.

PII: S0738-081X(09)00194-1

doi: 10.1016/j.clindermatol.2009.09.004

Clinics in Dermatology
Volume 27, Issue 6, Supplement , Pages S44-S47 , November 2009

Article Tools

* Image Usage & Resolution